Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition


Autoria(s): Mak, Milena Perez; Costa e Silva, Veronica Torres da; Martin, Regina Matsunaga; Lerario, Antonio Marcondes; Yu, Luis; Gehm Hoff, Paulo Marcelo; Castro Junior, Gilberto de
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures. Case report. We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO. This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.

Identificador

SUPPORTIVE CARE IN CANCER, NEW YORK, v. 20, n. 9, supl. 1, Part 3, pp. 2195-2197, SEP, 2012

0941-4355

http://www.producao.usp.br/handle/BDPI/37575

10.1007/s00520-012-1474-z

http://dx.doi.org/10.1007/s00520-012-1474-z

Idioma(s)

eng

Publicador

SPRINGER

NEW YORK

Relação

SUPPORTIVE CARE IN CANCER

Direitos

closedAccess

Copyright SPRINGER

Palavras-Chave #TUMOR-INDUCED OSTEOMALACIA #PROSTATE CANCER #BONE METASTASIS #HYPOPHOSPHATEMIA #FGF23 #FIBROBLAST-GROWTH-FACTOR-23 #HYPOPHOSPHATEMIA #ONCOLOGY #HEALTH CARE SCIENCES & SERVICES #REHABILITATION
Tipo

article

original article

publishedVersion